Insulet Corporation - Common Stock (PODD)
301.05
-0.57 (-0.19%)
NASDAQ · Last Trade: Jul 4th, 3:43 AM EDT
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · July 3, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · July 1, 2025
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process.
Via Investor's Business Daily · July 1, 2025
Via Benzinga · July 1, 2025

Via Benzinga · May 28, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via Chartmill · July 1, 2025
Via Benzinga · June 30, 2025
Via The Motley Fool · June 28, 2025
INSULET CORP (NASDAQ:PODD) shows strong revenue growth, high profitability, and a bullish technical setup, making it a noteworthy candidate for growth investors.
Via Chartmill · June 24, 2025
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.
Via StockStory · June 17, 2025
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · June 13, 2025
Stay updated with the S&P500 gap up and gap down stocks on Tuesday. Get a glimpse of the market's movement during today's session.
Via Chartmill · June 10, 2025
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts’ consensus estimates.
Via StockStory · June 10, 2025
Via Benzinga · June 9, 2025
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.
Via MarketBeat · June 9, 2025
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · June 6, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · June 6, 2025

While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Via StockStory · June 5, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers.
Via StockStory · June 4, 2025

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.
Via Benzinga · June 2, 2025

INSULET CORP (NASDAQ:PODD) shows strong growth fundamentals and a bullish technical pattern, making it a stock worth watching for investors seeking growth opportunities.
Via Chartmill · June 2, 2025

Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Via StockStory · June 2, 2025
INSULET CORP (NASDAQ:PODD) meets Minervini’s Trend Template with strong technicals and high growth fundamentals, making it a candidate for momentum investors.
Via Chartmill · May 20, 2025
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025